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Abstract
Iron deficiency and its associated anaemia (IDA) are the leadingBackground: 
forms of micronutrient malnutrition worldwide. Here we describe the rationale
and design of the first clinical trial evaluating the efficacy and safety of an
innovative nano iron supplement, iron hydroxide adipate tartrate (IHAT), for the
treatment of IDA in young children (IHAT-GUT trial). Oral iron is often ineffective
due to poor absorption and/or gastrointestinal adverse effects. IHAT is novel
since it is effectively absorbed whilst remaining nanoparticulate in the gut,
therefore should enable supplementation with fewer symptoms.
 IHAT-GUT is a three-arm, double-blind, randomised,Methods:
placebo-controlled phase II trial conducted in Gambian children 6-35 months of
age. The intervention consists of a 12-week supplementation with either IHAT,
ferrous sulphate (both at doses bioequivalent to 12.5 mg  /day) or placebo.
The trial aims to include 705 children with IDA who will be randomly assigned
(1:1:1) to each arm. The primary objectives are to test non-inferiority of IHAT in
relation to ferrous sulphate at treating IDA, and to test superiority of IHAT in
relation to ferrous sulphate and non-inferiority in relation to placebo in terms of
diarrhoea incidence and prevalence. Secondary objectives are mechanistic
assessments, to test whether IHAT reduces the burden of enteric pathogens,
morbidity, and intestinal inflammation, and that it does not cause detrimental
changes to the gut microbiome, particularly in relation to  , Lactobacillaceae
 and  .Bifidobacteriaceae Enterobacteriaceae
This trial will test the hypothesis that supplementation with IHATDiscussion: 
eliminates iron deficiency and improves haemoglobin levels without inducing
gastrointestinal adverse effects. If shown to be the case, this would open the
possibility for further testing and use of IHAT as a novel iron source for
micronutrient intervention strategies in resource-poor countries, with the
ultimate aim to help reduce the IDA global burden.
This trial is registered at clinicaltrials.gov ( ).Registration: NCT02941081
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Introduction
Iron deficiency anaemia (IDA) remains the most com-
mon forms of micronutrient malnutrition in the world today. 
Globally, IDA is estimated to affect 1.24 billion people, 
the majority of whom are children and women from resource-
poor countries, and is responsible for an estimated loss of 
35 million disability-adjusted life years (DALYs) (1.5% 
of total DALYs)1–3. IDA is estimated to cause more years 
lived with disability (YLD) than all other micronutrient 
deficiencies, haemoglobinopathies and haemolytic anaemias 
combined, and is the leading contributor to YLD in most low-
income countries1. Most sub-Saharan Africa countries have an 
anaemia prevalence above 40% in young children and pregnant 
women, a severe public health problem according to the World 
Health Organization (WHO)4. Iron deficiency is frequently 
exacerbated by concomitant parasitic and bacterial enteric 
infections and, together, these account for the majority of 
anaemia cases in developing countries5–7. The effects of 
anaemia on child cognition are also well recognised with 
several trials finding a combined 1.73 lower IQ points per 1 g/dL 
decrease in haemoglobin8. Even mild iron deficiency in the 
absence of anaemia appears to impair intellectual development 
in young children and is lowering national IQs, whilst overt 
IDA is associated with increased risk of serious morbidity, poor 
motor and mental development in children and impaired 
immunity.
The problem
Iron supplementation with simple ferrous salts is cheap and 
widely available, but constitutes a non-physiological approach 
to providing iron that has been associated with significant 
side-effects and adverse events9–15. Data and meta-analysis from tri-
als involving nearly 10,000 young children, mainly from resource-
poor countries, have consistently shown that conventional oral 
iron supplements used to treat IDA are associated with increased 
infection, including bloody diarrhoea10,13,16,17, detrimental changes 
to the gut microbiome and gut inflammation17–20. Therefore, in 
countries with poor infection control, iron supplementation in 
young children could further increase the burden from enteric 
infection and environmental enteropathy (i.e. persistent gut 
damage and inflammation that leads to malabsorption), which 
is a major cause of growth failure in children in resource-poor 
environments and may later exacerbate the risk of IDA21,22. 
Consequently, children living in areas where enteric infec-
tion is endemic remain without an effective and safe cure for 
ID and IDA, and, as such, it is perhaps not surprising that, 
despite considerable investment and effort, we have been unable 
to reduce the burden of this disease in young children in sub- 
Saharan Africa23.
Rationale and aims
Since 2005, we have been developing an engineered ana-
logue of natural food iron as an alternative iron supplement. 
Iron hydroxide adipate tartrate or IHAT, is completely different 
from other iron compounds currently used in supplementation 
or home fortification strategies since it defies the established 
dogma that iron absorption requires ionic solubilised iron to be 
taken up by the duodenal enterocytes. The novelty of IHAT, is 
precisely that it is not a soluble compound nor does it require 
solubilisation in the stomach prior to uptake by the enterocytes 
as it is taken up as whole nanoparticles by endocytosis24,25, simi-
larly to that proposed for dietary plant ferritin26–28. This means 
that the unabsorbed fraction of the compound that transits to 
the lower gut, which is usually at least 70% of all ingested oral 
iron, irrespective of the form, will remain nanoparticulate and, 
therefore not soluble, and as such should not be available to pro-
mote significant pathogen growth and tissue inflammation29,30. 
A crucial aspect of the IHAT nanostructure is that once it 
has entered the enterocyte it is sufficiently labile to break 
down effectively inside lysosomes/endosomes and deliver 
its iron because the native iron oxo-hydroxide structure (i.e. 
ferrihydrite) in IHAT has been purposely destabilised with the 
incorporation of dietary tartaric and adipic acids24,25,31, much 
in the same way as what occurs in the ferritin iron core due to 
interactions with the amino-acid residues in the protein shell32. 
Our pre-clinical and early-clinical data indicates that IHAT is 
effectively absorbed in humans, corrects IDA in animal mod-
els, is not redox reactive and does not have a detrimental impact 
on the gut microbiome24,29–31,33.
Aims
The main purpose of the IHAT-GUT study is to determine 
whether supplementation with IHAT safely corrects IDA in 
young children compared to the present standard of care. We 
hypothesise that 12-weeks supplementation with IHAT will 
correct iron deficiency and improve haemoglobin levels in 
            Amendments from Version 1
The revisions to the manuscript (version 2) are below:
- Highlighted the novelty in the abstract and Introduction
- Added the specific effects of IDA in children to the Introduction
- Added the additional subheadings suggested throughout
- Added sickle cell and thalassaemia separately in the exclusion 
criteria
- Noted that we have developed standardised protocols that are 
being used by trial staff for conducting all trial procedures. We 
also added that these methods can be made available upon 
request. (Follow up section)
- In the DSMB section we added the comment that there have 
been so far no interim analysis requested and that the current 
recommendation is for the study to continue as planned.
- We feel that we justified sufficiently in the manuscript how 
iron deficiency will be assessed (in the Outcomes section) and 
why we use the 1g/dL rise in Hb as an indication of efficacy 
(Discussion)
In relation to the complexity of the primary endpoints, we do 
appreciate this point and assure the reviewer that we thought very 
carefully about this and had several discussions with the several 
independent review boards that have approved this protocol.  We 
felt that maintaining the hypothesis-driven study design with the 
analysis of the 4 primary study endpoints is appropriate taking 
into consideration the stage of development of IHAT and the fact 
that at the end of this trial we must be able to make a ‘go/no-go’ 
decision to move to the next stages of trials in resource-poor 
settings. The ‘go’ decision to continue development of IHAT in 
these settings will only be justified if we determine in this trial if 
IHAT can help correct iron deficiency anaemia without promoting 
diarrhoea, which is the largest limitation of  current supplements. 
This is why we maintained the current 4 primary endpoints.
See referee reports
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young children without causing diarrhoea or inducing intestinal 
inflammation and detrimental changes in the gut microbiome.
Here we summarise the protocol for the IHAT-GUT study, the 
first clinical study to assess the efficacy and safety of IHAT in 
anaemic children living in resource-poor rural areas of The 
Gambia.
Protocol
Hypothesis and objectives
We will test the hypothesis that supplementation with IHAT 
eliminates iron deficiency and improves haemoglobin (Hb) levels 
in young children without increasing diarrhoea or promoting 
negative changes in the gut microbiome or inducing gut 
inflammation.
The IHAT-GUT study has four primary combined objectives 
to test efficacy and safety of IHAT. The primary objectives in 
terms of efficacy for this trial are to test non-inferiority of IHAT 
in relation to ferrous sulphate at correcting ID and improving 
Hb levels after 12 weeks of supplementation. The primary objec-
tives for safety are to test superiority of IHAT in relation to 
ferrous sulphate and non-inferiority in relation to placebo based 
on moderate-severe diarrhoea incidence and prevalence.
Secondary objectives of the IHAT-GUT trial are to test whether 
IHAT is non-detrimental with respect to enteric pathogen 
burden, does not increase morbidity, does not decrease abun-
dances of Lactobacillaceae and Bifidobacteriaceae relative to 
Enterobacteriaceae, and does not cause intestinal inflammation.
Study design and setting
Design. The IHAT-GUT trial is a three-arm, parallel, randomised, 
placebo-controlled, double-blind study with iron supplemen-
tation in young children with mild to moderate iron deficient 
anaemia. Ferrous sulphate (FeSO4), the current standard of 
care for iron supplementation, is used as the active comparator 
at the conventional daily dose of 12.5mg iron34. 
Children are randomised (1:1:1) to IHAT, FeSO4 or placebo, 
and each arm includes an intervention period of 12 weeks. 
The daily iron dose is 12.5 mg elemental iron bioequivalent.
Trial governance. The trial is being conducted in accordance 
with the ethical principles that have their origin in the Dec-
laration of Helsinki, and that are consistent with the Interna-
tional Conference on Harmonisation (ICH) requirements for 
Good Clinical Practice (GCP), and the applicable regulatory 
requirements. The study is sponsored by the London School 
of Hygiene and Tropical Medicine (LSHTM) and is conducted 
at the Medical Research Council (MRC) Unit The Gambia at 
LSHTM (MRCG). 
Setting. The study population in IHAT-GUT are children under 
the age of 3 years living in the north bank rural communities in 
the Upper River Region (URR) of The Gambia in West Africa. 
The URR has an approximate population of 200,000, and only 
one major town, Basse, and is otherwise typical of rural sub-
Saharan Africa. The temperature varies between 15°C and 
40°C, but can reach as high as 46°C in the north bank. There 
are distinctive dry (November to May) and wet (June to 
October; mean annual rainfall = 876 mm) seasons. According 
to the most recent Gambia Demographic and Health Survey35, 
the URR has the highest under-5 mortality rate in the country 
(92 deaths per 1000 livebirths), the highest percentage of 
severely malnourished children (7–11%), and the highest 
prevalence of malaria and anaemia in children under 5 years 
(4.5% and 82.5%, respectively). Severe anaemia in children is 
highly prevalent in these communities, with 22.4% of children 
under 5 years having haemoglobin below 8 g/dl35. Diarrhoeal 
diseases are also common36,37. Therefore, there is a clear clinical 
need for safe and effective iron supplementation strategies in 
these communities.
The study area includes 45 villages in the Wuli and Sandu 
districts (Figure 1), situated on the north bank of the river 
Gambia, approximately 400 km east of the capital Banjul, with 
a population of approximately 2800 children aged 6–35 months. 
All communities have access to borehole tap water at central 
places. Study specimen samples are collected at one of the study 
health clinics: Yorrobawol health center, Darsilami community 
health post, Konkuba community health post, Taibatu health 
post and Chamoi Health Center (Figure 1). Samples are trans-
ported in cold boxes to the study laboratory in Basse for 
sample processing and analysis, and from there to the Keneba 
and Fajara laboratories, or to external laboratories for further 
analysis.
Study participants
Participants are young children and the study protocol is 
explained to their parents orally by the field staff. An impartial 
witness is present during consent for all illiterate parents and 
also signs the consent form next to the parent’s thumb print. No 
children start any study specific procedure without full, written 
informed consent being first obtained. A copy of the study 
information sheet and signed consent form is provided to 
those consented (Supplementary File 1). Parents are free to 
withdraw their consent at any time. Participants must meet 
all of the inclusion criteria and none of the exclusion criteria 
to be eligible for the trial.
Inclusion criteria: Apparently healthy; 6–35 months old; free 
of malaria; with IDA defined as 7≤ Hb <11 g/dl and ferritin 
<30 μg/l38; resident in the study area (and planning to remain in 
the study area for the duration of the trial); able and willing to 
comply with the study protocol; informed consent given by 
parent.
Exclusion criteria: Congenital anomalies/birth defects (except 
minor external congenital malformation); severe malnutrition 
(z-scores for length/height-for-age (HAZ), weight-for-age 
(WAZ), weight-for-length/height (WHZ) <-3 standard deviations 
(SD); shock syndrome; chronic conditions; sickle cell and tha-
lassaemia; currently participating in another study; currently 
taking iron supplements/multiple micronutrient supplements; 
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currently experiencing moderate-severe diarrhoea, defined as 
those diarrhoea episodes where (i) the child passes more than 
five loose or watery stools per day, (ii) there is blood in the 
stool (dysentery), or (iii) the child shows signs of clinical dehy-
dration (assessed by the study nurse based on physical signs 
such as little or no urination, sunken eyes, and skin that lacks 
its normal elasticity).
Recruitment and screening
Prospective participants are identified through the enumera-
tion data collected by the study field team in the 45 study 
villages. The communities and regional health teams in the 
study area have been sensitised to the study. The field team 
visits the parents of all young children identified as prospective 
participants to explain the study and answer any questions they 
may have, those interested in taking part in the study are then 
invited to attend a screening visit at one of the study health 
facilities. At screening, the child is physically examined by 
a study nurse or clinician; those potentially eligible to take 
part in the study have their height and weight measured and a 
finger prick blood sample collected for Hb measurement and 
rapid diagnostic testing (RDT) for malaria. Children with Hb 
<7 g/dl or those severely malnourished cannot be enrolled and 
are referred to the regional health centre for treatment according 
to national guidelines. Malaria-positive children (positive RDT 
and confirmation by blood film) are not enrolled and will be 
treated according to national guidelines. If HAZ, WAZ, WHZ 
are all above -3 SD, 7≤ Hb <11 g/dl and the RDT is negative, 
then a small venous blood sample is collected by the study 
nurse to send to the laboratory for confirmation of Hb levels 
and determination of serum ferritin. If 7≤ Hb <11 g/dl and 
serum ferritin < 30 ng/ml, the child is invited to a pre-enrolment 
day back at the clinic (Day 0), which is 4–5 weeks after the 
screening visit, for a finger prick to confirm absence of malaria 
by RDT and haemoglobin concentration.
Randomisation and blinding
Randomisation is based on a stratified block design to achieve 
group balance in terms of age and baseline haemoglobin 
concentration. Based on the assessments at the pre-enrolment day 
(Day 0), each child is categorised into two Hb classes (below or 
equal to/above the median Hb for the recruited cohort) and also 
according to age into 3 classes (6–11 months, 12–23 months 
and 24–35 months). This divides children into 6 different strata 
and in each strata the children are randomly assigned to one 
of the three study treatment arms (1:1:1 ratio) using R version 
3.4.3 and a block randomisation approach with fixed block 
size determined by age and Hb levels.
Randomisation is performed by the study statistician who remains 
blinded to the treatment codes. Participants, parents and the 
entire study team are blinded as to which intervention/treatment 
arm participants belong to. Each child has a unique interven-
tion code which is also their study ID/randomisation number, 
this means that the study team is unaware of which children 
belong to the same treatment arm. The child study ID is the same 
Figure 1. Map of Upper River Region in The Gambia, with location of study clinical facilities. Study samples are collected at one of the 
clinical facilities, Yorrobawol health center, Darsilami community health post, Konkuba community health post, Taibatu health post and Chamoi 
Health Center, and transported to the study laboratory in Basse for sample processing and analysis, and from there to other laboratories for 
further analysis. Map adapted from the Atlas of the Gambia 2004.
Page 5 of 22
Gates Open Research 2018, 2:48 Last updated: 15 OCT 2018
code that is used to label the capsules for the study treatment 
they receive (see below). If emergency unblinding is required, 
only the particular study subject in question will be unblinded, 
since each participant has a unique treatment code. Following 
investigation by the Data and Safety Monitoring Board (DSMB) 
of an emergency unblinding case, and only at the request of 
the DSMB, we may also unblind a whole treatment arm or 
the entire study. In all cases, someone independent from the 
trial team will perform the unblinding.
Interventions
In each arm, children receive a daily dose of either IHAT, FeSO4 
or placebo for 12 weeks. Children in the ferrous sulphate arm 
receive 12.5 mg elemental iron equivalent daily, as FeSO4.H2O, 
in line with WHO recommendations34 and Gambian national 
guidelines for the 6–35 months age group. Children in the IHAT 
arm receive 20 mg elemental iron equivalent daily, which is the 
bioequivalent dose considering the bioavailability of IHAT 
relative to FeSO4. Children in the placebo group receive ca. 
30 mg pharmaceutical grade sucrose daily. All three materi-
als are formulated with 6 mg of a food colourant for colour 
matching and each daily dose is contained in a powder-filled 
easy-open capsule. Capsules for each treatment are packed in 
medicine bottles, each bottle containing enough capsules for one 
child for the entire study duration, and these bottles are indi-
vidually labelled with the child’s unique study ID, which is their 
randomisation code, as described above. All capsules appear 
identical and the powders inside them do not have any appar-
ent visual differences in texture or colour. Every day the field 
worker visits each child and provides them with the daily 
dose of their allocated treatment. For each child, the field 
worker opens one of their allocated capsules and adds all its 
contents to a small amount of a local juice drink, in a disposable 
plastic cup, immediately before administration directly into 
the child’s mouth. There are no apparent differences in the 
colour, turbidity or taste of the powder and juice mixes. Before 
administration, the mother is encouraged to feed the child so 
that the supplements are not ingested on an empty stomach.
Besides the study interventions mentioned here, children do 
not receive any other concomitant interventions or supplements 
during the 12-week intervention period, but all children are 
followed up weekly by the study clinical team, and any clinical 
conditions are treated following national guidelines.
Follow-up study visits
A flow chart of the study participant timeline is presented in 
Figure 2. On study Day 1, i.e. the first day of supplementation, 
each child is invited back to the study clinic and a photo 
is taken (with consent) for a study ID card that also con-
tains the child’s randomisation/study ID number. At this visit, 
demographic and immunisation data are collected and the 
study morbidity questionnaire is completed (Table 1). A venous 
blood sample and a stool sample are also collected (study 
baseline samples). After blood collection, the field staff give the 
child their allocated study arm supplement.
Every day over the following 12 weeks, the field staff visits 
the child at home in order to administer the allocated study 
supplement and to check on the child’s health status. They com-
plete the study morbidity questionnaire three times per week, 
which includes questions regarding fever, diarrhoea, vomiting, 
malaria symptoms, other illness, hospitalisation, appetite and med-
ication. If a child is found unwell they are referred to the study 
nurse or clinician for evaluation and treatment. These check-ups 
continue 4 weeks post-supplementation to follow-up on adverse 
events.
Each week during the study supplementation period, children 
are invited back to the study clinic for a check-up by the study 
nurse and a finger prick to determine their malaria and Hb 
status. Children found with a positive RDT at any time during the 
supplementation period are further tested with a blood film and 
treated according to The Gambian national guidelines if malaria 
is confirmed. Any child where Hb falls below 7 g/dl during the 
supplementation period, discontinues the study supplementation 
and is offered standard-of-care oral iron treatment according to 
the national guidelines. These children continue to be followed 
up by the clinical team at the weekly clinics and will not be 
excluded from the data analysis but considered as treatment 
failures.
On study days 15 and 85, the child visits the study clinic and 
stool and venous blood samples are collected. Immunisation 
data is also recorded on these occasions. Height and weight is 
re-measured on study Day 85.
Venous blood samples are collected in S-Monovette® blood col-
lection tubes either before the first meal of the day or, when 
this is not possible, at least 1 hour after the last meal. All blood 
samples are kept cool before transport to the Basse labora-
tory for processing. Stool samples are collected at home in toilet 
pots provided by the study team and lined with a disposable 
plastic liner at study days 1, 15 and 85. Stool samples can be 
collected within 7 days of the study time-point when it becomes 
difficult to collect the sample on that exact day, i.e. if the 
child travels or is not able to pass stool. The stool samples are 
aliquoted by the field staff as soon as possible after collection 
into a sterile Sarstedt stool collection tube and an OMNIgene® 
GUT sample collection kit (DNA Genotek).
At the end of the study follow-up period (i.e. Day 113), the 
children in any arm who still have anaemia (Hb<11 g/dl) 
are provided with standard-of-care iron supplementation for 
three consecutive months as per Gambian national and WHO 
guidelines.
Standardised protocols have been developed and are being 
used by all trial staff for conducting all field, laboratory and 
data procedures employed in this study. All deviations to these 
procedures is promptly reported following the study sponsor 
procedure and ICH-GCP guidelines. These methods can be 
made available upon request.
Outcomes
All participants are assessed at three different time-points: at 
baseline (Day 1 of supplementation), and at 15 and 85 days after 
start of supplementation. The Day 15 time point will provide 
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an indication of acute compound-related effects and the Day 
85 time-point will be indicative of chronic (i.e. longer term) 
compound-related effects, for all the ‘safety’ outcomes.
The primary efficacy outcome of the trial is the proportion of 
children in each arm who resolve iron deficiency and either 
achieve a normal Hb or show an increase of at least 1 g/dl after 
12 weeks of supplementation (i.e. at study Day 85). The primary 
safety outcome is the burden of moderate-severe diarrhoea. 
Therefore, there are four primary endpoints of the trial: (1) iron 
deficiency at Day 85; (2) Hb levels at Day 85; (3) ‘incidence 
density’ of moderate-severe diarrhoea over the 12 weeks (i.e. 
the number of new moderate-severe diarrhoea episodes per child 
over the 12 weeks supplementation period); (4) ‘period preva-
lence’ of moderate-severe diarrhoea over the 12 weeks sup-
plementation period (i.e. the proportion of children with at least 
one episode of moderate-severe diarrhoea in this period). To 
assess iron deficiency, we will use regression-adjusted ferritin 
concentration below 12 μg/l, where ferritin values are adjusted 
for inflammation using the regression model recommended 
Figure 2. Consort 2010 flow diagram.
Allocation
Allocated to FeSO4 (n= 200) Allocated to Placebo (n= 200)Allocated to IHAT (n= 200)
12-week intervention 12-week intervention 12-week intervention
4-week follow-up
post-intervention
4-week follow-up
post-intervention
4-week follow-up
post-intervention
Assessment at Enrollment (Day 0)
Excluded (n= ?)
Not meeting inclusion criteria
Declined to participate
Other reasons
Assessed for eligibility (n= ?)
Analysed (n= ?) Analysed (n= ?) Analysed (n= ?)
Screening
Randomized (n= 600)
Follow-up post-intervention to Day 113
Analysis
Assessment at baseline (Day 1)
Assessment at Day 15
Assessment at Day 85
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by the Biomarkers Reflecting Inflammation and Nutritional 
Determinants of Anemia (BRINDA) group6.
Iron deficiency and Hb levels at Day 85 will be used to assess 
non-inferiority of IHAT relative to FeSO4 in terms of efficacy 
at treating IDA. We will determine the proportion of children 
in each arm who resolve iron deficiency and either achieve a 
normal Hb (≥ 11 g/dl) or an increase in Hb of at least 1 g/dl 
after 12 weeks of iron supplementation.
‘Incidence density’ and ‘period prevalence’ of moderate-severe 
diarrhoea will both be used to assess superiority of IHAT 
relative to FeSO4 and non-inferiority relative to placebo for the 
diarrhoea outcome (i.e. safety or tolerability). Moderate-severe 
diarrhoea is defined as those diarrhoea episodes where: (i) the 
child passes more than five loose or liquid stools per day, 
(ii) there is blood or mucus in the stool (dysentery), or (iii) the 
child shows signs of clinical dehydration (assessed by the study 
nurse based on physical signs such as little or no urination, 
sunken eyes, and skin that lacks its normal elasticity).
Secondary endpoints are faecal microbiome diversity and profile 
(particularly in terms of abundance of Enterobacteriaceae, 
Bifidobacteriaceae, Lactobacillaceae), abundance of enteric 
pathogens, faecal calprotectin (marker of gut inflammation), hos-
pitalisation and morbidity (data collected three times per week 
using the study questionnaire), malaria infection (data collected 
every week with RDT), treatment failures (i.e. the number of 
children who have to discontinue study supplementation because 
their Hb falls below 7 g/dl), the proportion of days a child has 
diarrhoea over the intervention period (‘longitudinal prevalence’ 
of diarrhoea), the proportion of days a child has moderate-severe 
diarrhoea over the intervention period (‘longitudinal prevalence’ 
of moderate-severe diarrhoea), ‘incidence density’ of bloody 
diarrhoea (i.e. the number of bloody diarrhoea episodes per 
child-month of observation), markers of systemic inflammation 
(serum C-reactive protein (CRP) and alpha 1-acid glycoprotein 
(AGP)), and systemic markers of iron status (hepcidin, 
soluble transferrin receptor (sTfR), transferrin saturation and 
circulating non-transferrin bound iron - NTBI).
Laboratory evaluations
Unless otherwise stated, all laboratory evaluations are carried 
out at the laboratories of the MRCG.
Blood samples. In the venous blood samples collected on study 
Days 1, 15 and 85, the following parameters are assessed: full 
haematology panel (using a MedonicTM Haematology Analyzer 
Table 1. Overview of the study morbidity questionnaire.
Category Questions
Diarrhoea
Any diarrhoea? 
If yes, duration (days) 
If yes, number of stools per day 
If yes, is there blood/mucus in stool? 
Is the child urinating less? 
Is the child lethargic or unconscious? 
Is the child restless and irritable? 
Does the child have sunken eyes? 
Is the child drinking poorly? 
Is the child thirsty, drinking eagerly? 
Does the skin pinch go back slowly?
Fever
Axillary temperature 
History of fever? 
If yes, number of days
Cough
Cough? 
If yes, duration of cough (days)
Vomiting
Has the child been vomiting since last visit? 
If yes, number of days
Appetite
How is your child’s appetite? 
If decreased, number of days 
If decreased, describe
Medication
Has the child been or is on any medication since last visit? 
If yes, please state the medication
Other
Difficulty breathing? 
Convulsion? 
Has the child had any other illness since last visit? 
If yes, describe
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M-Series, Boule Diagnostics AB); serum ferritin, sTfR, serum 
iron and total iron binding capacity (for calculating transferrin 
saturation), CRP, AGP (using a fully automated biochemistry 
analyser Cobas Integra 400 plus); serum hepcidin (using the 
DRG® Hepcidin 25 (bioactive) HS ELISA); serum NTBI 
(using a fluorescent beads assay39, at an external laboratory 
in the U.K.). In the weekly finger prick blood samples, Hb is 
determined using a HemoCue® Hb 301 system and RDT is 
performed using the SD Bioline Malaria Ag P.f. test (Standard 
Diagnostics, Inc.), these evaluations are conducted at the field 
study clinics.
Stool samples. Stool samples collected in the OMNIgene® 
GUT tube contain a DNA stabilising agent that ensures that 
samples can be kept at ambient temperature for 60 days. Total 
stool DNA is extracted from these samples using the Mo Bio 
PowerLyzer® PowerSoil® DNA Isolation Kit (Qiagen) within 
6 weeks of sample collection. Stool DNA will be used for 
microbiome 16S rRNA sequencing (Illumina MiSeq platform), 
which will be conducted at an external laboratory in the U.K., 
and also for targeted qPCR of enteric pathogens.
In the stool samples collected in the Sarstedt stool collection 
tube the following parameters are assessed: calprotectin (using 
the Bühlmann fCAL® ELISA) and helminth egg count (using the 
Kato-Katz method40).
Data collection and data management
A password-protected study database has been established 
using the Research Electronic Data Capture (REDCap) secure 
web-based application based in PHP and MySQL. Access to 
the database is only given to members of the study team and 
the trial monitors and the database is managed by a dedicated 
data manager. All field data is captured in electronic case report 
forms (eCRF) and entered directly into handheld tab-
lets (Samsung Galaxy Tab A (2016) SM-T580) using the 
Android 7.0 software and the REDCap mobile app. Data is 
synced daily into the database via secure Wi-Fi network.
The following data is recorded: date of informed consent, per-
sonal data (ID, initials, date of birth), socioeconomic data, 
height and weight, information on health status and regarding 
participation in other studies, date and time of all venous and 
finger prick blood collections, date and time of all faecal 
sample collections, date and time of supplement administration, 
data on morbidity, adverse events, lab results.
Sample size
The hypotheses being tested in this study are:
1.    Non-inferiority of IHAT compared to ferrous sulphate 
for correction of iron deficiency and either achieving 
a normal Hb or an increase of at least 1 g/dl after 
12 weeks of iron supplementation. A non-inferiority 
margin of 0.1 is used. The null hypothesis is therefore 
the probability in the IHAT arm minus the response 
probability in the ferrous sulphate arm is less than or equal 
to –0.1.
2.    Superiority of IHAT compared to ferrous sulphate in 
terms of incidence density of moderate-severe diarrhoea. 
Here the null hypothesis is that the mean number of new 
episodes in the IHAT arm is greater than or equal to the 
mean number in the ferrous sulphate arm.
3.    Superiority of IHAT compared to ferrous sulphate in 
terms of prevalence of moderate-severe diarrhoea. Here 
the null hypothesis is that the prevalence of diarrhoea in 
the IHAT arm is greater than or equal to the prevalence 
in the ferrous sulphate arm.
4.    Non-inferiority of IHAT compared to placebo in terms 
of prevalence of moderate-severe diarrhoea. Here the 
null hypothesis is that the prevalence of diarrhoea in 
the placebo arm minus the prevalence in the IHAT arm 
is less than or equal to – 0.1.
Because this is a preliminary study, with any significant results 
being retested in a subsequent pivotal study, we do not adjust 
for multiple testing. Each hypothesis is to be tested at a 10% 
one-sided type I error rate.
A sample size of 600 subjects completed equally randomised 
between the three arms, provides high power for each of the four 
hypotheses:
1.    An 89% power to test non-inferiority on the IDA response 
probability, with a non-inferiority margin of 0.1 (0.583 
on the odds ratio scale) assuming that the true response 
probability is 0.3 on IHAT and ferrous sulphate10,13,41 
arms.
2.    A 90% power to test superiority for the incidence 
density of moderate-severe diarrhoea outcome assum-
ing IHAT provides a 20% reduction in the mean for 
ferrous sulphate (i.e. from 1.28 episodes per child over 
the 12 weeks supplementation period to 1.02; calcula-
tions based on unpublished data for studies with iron 
supplements in rural Gambia).
3.    A 90% power to test reduction in prevalence of moder-
ate-severe diarrhoea from 25% in the ferrous sulphate 
arm to 15% in the IHAT arm.
4.    A 93% power to test non-inferiority (0.1 non-inferiority 
margin, 0.583 on the odds ratio scale) of IHAT against 
placebo for prevalence of moderate-severe diarrhoea 
when both have 15% prevalence. For these calculations, 
we used published diarrhoea period prevalence data 
from studies with iron supplementation13,17.
For the secondary outcomes, the trial (n=200 per arm) will have 
over 85% power to detect significant differences between all 
the arms in terms of enterobacteria17, NTBI39 and calprotectin17.
To account for a non-completion rate of ca. 15%, the total 
number of children we plan to enrol in the study is n=705.
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Statistical analysis
A full statistical analysis plan will be finalised prior to database 
lock and before breaking the randomisation code. We summarise 
briefly the planned statistical analysis here.
For the IDA response and diarrhoea prevalence outcomes, we 
will fit a logistic regression, adjusting for the strata created by 
age and Hb level groups prior to enrolment. For non-inferiority 
comparisons, the odds ratio for effect of IHAT relative to the 
relevant comparator arm will be estimated, and if the lower 
90% one-sided confidence interval is above 0.583 (equivalent 
to the 10% non-inferiority margin above), non-inferiority will 
be declared for IHAT. For superiority comparisons, the data 
will be analysed in a similar way but superiority will be 
declared if the one-sided p-value for the Wald test of the effect 
of IHAT is less than 0.1.
For the diarrhoea incidence endpoint, a Poisson regression with 
treatment arm as predictor will be fitted to the data adjusting 
for the strata.
For the primary non-inferiority hypothesis, we will conduct 
per-protocol and intention-to-treat analyses and for the superiority 
hypotheses we will conduct intention-to-treat analyses.
The secondary endpoints will be tested using linear regression 
with the treatment arm, age and Hb level as covariates.
Multiple imputation will be used to account for missing data if 
there are missing covariates in more than 5% of participants. 
If there is substantial difference in the loss-to-follow-up rate in 
the different arms we will consider applying simple sensitivity 
analyses to investigate the robustness of results.
Ethics statement
This study is being conducted in accordance with the ethical 
principles that have their origin in the Declaration of Helsinki, 
and that are consistent with the ICH GCP requirements, and in 
keeping with local regulatory requirements.
Scientific advice on the study protocol has been given by the 
UK Medicines and Healthcare products Regulatory Agency 
(MHRA 1400, 21/12/2016). The study protocol and any sub-
sequent amendments have been reviewed and approved by The 
Gambia Government/MRC Joint Ethics Committee (reference 
SCC1489). Clinical Trials Authorisation has been granted by 
the Medicines Control Agency, The Gambia (HP373/347/16/
MJK(80)).
This paper is written following the SPIRIT 2013 guidelines42 
(Supplementary File 2). The trial is registered in ClinicalTrials.
gov, identifier: NCT02941081 (registration date: 21 Oct 2016; 
https://clinicaltrials.gov/ct2/show/NCT02941081).
Data and safety monitoring
An independent local safety monitor (LSM) and an independ-
ent Data and Safety Monitoring Board (DSMB) have been 
appointed to monitor quality control of the data, progress of 
recruitment and safety aspects of the IHAT-GUT trial, including 
the regular review of all adverse events. The LSM reviews 
adverse events monthly and the DSMB reviews adverse events 
quarterly during the study. Any serious adverse events are 
reported in real time to both the LSM and the DSMB.
No interim analysis will be conducted unless requested by 
the DSMB in response to adverse events. By August 2018, 
no interim analysis had been requested by the DSMB and the 
most recent recommendation was for the study to continue as 
planned.
Trial monitoring
Trial oversight is provided by the Sponsor through the Clinical 
Trials Department at MRCG. An independent trial monitor regu-
larly reviews good clinical practice (GCP) compliance, quality 
of data collection, sample analysis and the progress of the trial.
Informed consent
All field workers taking part in the recruitment of participants 
have received GCP and informed consent training prior to 
study start. These field workers have also been trained on trans-
lating the contents of the information sheet into the different 
local languages. The field staff explain details of the study to 
illiterate parents in a language they understand, in the presence 
of an impartial literate witness, and in a room which ensures 
adequate privacy. The literate parents are allowed to read the 
information sheet in their own time. Parents are given enough 
time to ask questions and decide if they want their child to par-
ticipate. No child starts any study specific procedure before 
informed consent is obtained. Participants will not get any remu-
neration for taking part in the study but will have access to free 
medical care for the duration of the study. Participants are 
protected in accordance with the study Sponsor Clinical 
Trial/Non Negligent Harm Insurance and Medical Malpractice 
Insurance.
Confidentiality
Each participant is allocated an individual identification (ID) 
number, which is used to label all samples collected for the 
study and on the eCRF during the course of the study. All 
data is linked-anonymised and the linkage to the ID is not be 
possible without a lookup table, which is held only by the data 
manager and designated data staff during the course of the study. 
Once data collection is complete, analysis will be performed on an 
anonymised copy of the dataset. At all stages, staff/collaborators 
responsible for sample analysis will be blinded as to the sub-
ject’s identification. Together, these processes will ensure 
complete confidentiality of the data gathered and impartiality 
of data analysis.
Dissemination and data access
Results of the study will be submitted for publication in 
relevant peer-reviewed open-access journals and key findings 
presented at international scientific meetings. The main find-
ings will be disseminated to the National Nutrition Agency and 
the Ministry of Health in The Gambia. If this study suggests a 
possible benefit of IHAT above ferrous sulphate, contact will be 
made with key international organizations (e.g. WHO, UNICEF) 
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and funding bodies to plan future pivotal trials. Any request 
for use of study data will have to be approved by the study 
Sponsor and the Ethics Committee. Data will only be made 
available in an anonymous format to external users. Data shar-
ing will be in agreement with the Sponsor policy on research 
data sharing and with the Bill & Melinda Gates Foundation 
Global Access requirements.
Study status
Screening for enrollment started in November 2017 and by 
August 2018, 645 subjects have been successfully recruited and 
randomised. The first patient first visit (Day 1) was on January 
8, 2018. Field data collection will be completed in December 
2018. Analysis, and submission for publication, of primary 
endpoint results will be completed by March 2019. The current 
protocol version is SCC1489 V5.0, 21 May 2018.
Discussion
Rationale for enrolling young children as the study 
population group
Young children living in resource-poor rural areas in sub- 
Saharan Africa, where there is high burden from diarrhoeal 
diseases, are one of the main population groups in need of safer 
forms of iron supplementation. Randomised-controlled clini-
cal trials conducted in nearly 10,000 young children living in 
developing countries have consistently shown that current forms 
of iron supplements are associated with increased infection, 
including bloody diarrhoea10,13,16,17, and detrimental changes to 
the gut microbiome and gut inflammation17,18,43, further increas-
ing the burden from enteric infection and environmental enter-
opathy (i.e. persistent gut damage and inflammation that leads to 
malabsorption), which is a major cause of growth failure in 
children in resource-poor environments21,22. Furthermore, it 
appears that these effects are much more relevant in those 
resource-poor countries where enteric infection risk is higher 
and in the pre-school age group, since in older South-African 
children, with a low enteropathogen burden, iron supplementa-
tion does not appear to significantly affect the dominant bacterial 
groups in the colon or to increase gut inflammation44.
If IHAT shows a benefit in the proposed trial, where it will 
be tested in the population group that is most sensitive to the 
gastrointestinal adverse effects of iron supplementation, then 
we believe it can be effective in any other population group. 
However, the reverse is not true, if IHAT was tested and found 
to be effective in adults or older children, it would not mean 
it would work in the young children group, since these have 
the most immature guts where the microbiome is not stable and 
where the mucosa is more susceptible45–48.
The health of all children in our study is monitored daily, as are 
all adverse events, including all diarrhoea episodes, malaria 
and other co-infections. Thus, ethically we are not subjecting 
children to any unnecessary risk or, in fact, any added risk 
beyond that expected with current iron supplements when used 
as per national guidelines.
Rational for inclusion of a placebo group
Due to the possible detrimental effect of iron supplements in 
pre-school age children, particularly those living in resource-poor 
settings10,13,16–18,43, there is now a strong rationale for a ‘no 
iron’ (placebo) control group thus leading to ethical equipoise. 
Furthermore, in these settings, there have been numerous 
randomised-controlled trials with iron supplementation in young 
children that have failed to show a significant decrease in anae-
mia prevalence or a clinically relevant increase in haemoglobin 
after intervention with iron supplements10,13,41, as such the active 
control or standard treatment does not have proven efficacy in 
this setting. Furthermore, in The Gambia there is no national 
screening program or mandatory iron supplementation or home 
fortification policy for children, even though the prevalence of 
anaemia in this age group is extremely high35. 
Therefore, inclusion of a placebo arm in this trial adheres to the 
guidelines for non-inferiority trials as stipulated in the ICH guid-
ance Choice of Control Group and Related Issues in Clinical 
Trials (ICH E10) stating that “where there is no serious harm, 
such as death or irreversible morbidity in the study population, 
it is generally considered ethical to ask patients to participate 
in a placebo-controlled trials, even if they may experience 
discomfort as a result, provided the setting is non-coercive and 
patients are fully informed about available therapies and the 
consequences of delaying treatment”49.
Rational for treatment effect sizes
Because many trials conducted in children from resource-poor 
countries with ferrous sulphate or ferrous fumarate supplemen-
tation have still failed to provide anaemia resolution in inter-
ventions shorter than 6 months, we considered that an increase 
of 1 g/dl in haemoglobin after 3 months is an indication of 
treatment efficacy. We have based our assay sensitivity on data 
published with relevant iron supplement studies in children 
available in the literature10,13,41. Nonetheless, we plan to also 
use the data collected in this study to conduct an exploratory 
analysis for assay sensitivity, using the comparisons between 
the active control and the placebo arms to determine the true 
effect size of iron supplementation in this population group. This 
is important since assay sensitivity is an essential property of 
a non-inferiority trial, allowing us to determine if both iron 
supplements are effective or if neither was effective as per FDA 
guidelines50. These data will be very useful so that adequate 
treatment effect sizes can be used to power any future studies, 
in particular a pivotal trial, both for ferrous sulphate and 
IHAT supplementation effects.
Additionally, efficacy comparisons with the placebo group 
will tell us if iron supplements are preventing haemoglobin 
from decreasing further and preventing severe anaemia as 
children grow, which we consider to be a positive effect, even 
when overall anaemia prevalence may not decrease for this age 
group due to the high demands for iron during fast growth.
In terms of safety, the placebo arm will also allow us to rule-out 
any negative impact of IHAT on diarrhoea episodes, the gut micro-
biome and infection risk.
Mitigation of risk of malaria and co-infections
There are risks associated with a large intake of iron supple-
ments, especially in areas of malaria endemicity. The dose 
of iron given daily in the reference arm (12.5 mg) is the 
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recommended by WHO for this age group in non-malarious areas 
or malaria-endemic areas where it should be implemented in con-
junction with measures to prevent, diagnose and treat malaria 
and co-infections34. The iron dose in the IHAT arm (20 mg) is 
the bioequivalent dose, i.e. the same absolute amount of iron 
should be absorbed as in the ferrous sulphate arm, and because 
IHAT should be safer to the gut, the unabsorbed fraction should 
not cause detrimental effects, such as infectious diarrhoea. This 
dose (20 mg Fe) is still less than the new WHO recommendation 
for children in the 24–35 month age group (i.e. 30 mg,34).
In any case, in this study with the daily visits by the field staff 
and the weekly visits to the study clinics, all children are closely 
monitored and at the first sign of infection or malaria they are 
referred to the study nurse or clinician for clinical assessment 
and treatment as per clinical guidelines.
Conclusions
This study will provide the first clinical trial data for IHAT, an 
innovative nano-iron supplement, and will enable us to obtain 
high-quality data for its safety and efficacy in correcting iron 
deficiency and improving anaemia in sub-Saharan African 
children, the population group most in need of a better oral iron 
supplement.
The trial will also contribute to our better understanding of iron 
deficiency and anaemia treatment effect sizes with the current 
gold-standard of iron supplementation, and to our understand-
ing of how iron supplementation and iron deficiency impact 
on enteric infection and diarrhoea risk.
If IHAT is successful in this trial, these data will provide the 
evidence needed to encourage further development so that IHAT 
can be implemented as a novel iron source for use in micro-
nutrient intervention strategies aimed at children and women 
living in resource-poor countries and, hence, help to reduce the 
global burden of IDA. We envisage that a future phase III 
pragmatic trial would test efficacy and safety of IHAT, used 
as part of multi-micronutrient supplements, in children and 
pregnant women across multiple countries.
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This article is very well planned and well resourced. The project is highly relevant to treatment of anemia.
To provide a FeSO  substitute of equivalent activity is an important advance. This is not glamorous work
but the possible replacement of FeSO  by an alternate iron source is extremely important, as compliance
with FeSO  can be poor.
A relatively new development in this type of work is to study any changes induced in the gut flora. The
results from this part of the proposed study will certainly be interesting, but may be difficult to interpret.
The clinical trial includes a placebo as well as a FeSO  control. This is important, as many such trials
include one or the other, but not both. The direct comparison of the three different conditions will facilitate
the interpretation of the clinical data.
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Is the study design appropriate for the research question?
4
4
4
4
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Many thanks for asking me to review this trial protocol. This trial offers a potential breakthrough to one of
the biggest diseases worldwide.
Iron deficiency is the most common nutritional disease worldwide. A disease that impacts people form
countries of all GDP. Iron deficiency is the commonest cause of anaemia and associated with 8 years of
living with disability. Iron deficiency and anaemia are so common they are hidden in plain sight.  
In low income countries, the situation is worsened due to poor diet (low in meat, which has good iron
absorption) and concurrent infections (which reduce iron absorption). Iron deficiency leads to childhood
growth retardation and reduced cognitive development. In adults’ iron deficiency impacts mental and
physical performance. In pregnancy the situation worsens with a higher risk of intrauterine growth
retardation and death to both mother and baby at childbirth.
A key problem to iron deficiency is lack of available good therapies. First line is dietary modification and
then iron tablets. Iron tablets are essentially iron salts. The iron is poorly absorbed (only 5%) the
remainder sits in the gut causing local toxicity, side effects and potentially exacerbating infection. An
alternative is an iron infusion. This is simply not available or possible in many populations let alone in
those countries who cannot afford healthcare.
There is little funding to trials with simple and cheap solutions and no new oral iron preparations in the last
decade. The Gates Foundation are to be applauded to support this work.
 
Main Comments
Overall, this manuscript would benefit from being shortened and simplified. The message that this is a
novel oral iron with a unique absorption pathway that may impact anaemia management without GI side
effects does not come through. The authors should not under estimate the novelty of the invention of a
nano-iron and how this works
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nano-iron and how this works
For a full protocol it can be difficult as there is so much information. The main issue is complexity of the
primary endpoint. It is very unusual to have 4 primary endpoints. This leads to a lot of confusion in the
hypothesis, aim(s) objectives and methods. Ideally this should be one key primary endpoint or in this case
one efficacy and one safety endpoint. It is not a Multiarm multlistage or adaptive trial so randomising to 3
groups with 4 primary endpoints is difficult. Perhaps, broach this early on and explain (I suspect) the
funder's and sponsors requirement for the additional endpoints, then refer to efficacy and safety
endpoints moving forwards.
 
Abstract
Please simplify and shorten and explain what IHAT is and why it is relevant:
Oral iron is often ineffective as poorly absorbed and associate with gut side effects. IHAT is a novel
nano-iron preparation with high efficacy and >50% absorption therefore overcoming these issues
enabling lower dosage than conventional therapy with fewer side effects.
Is this a Phase 2a? efficacy trial to test non-inferiority of IHAT to treat anaemia compared to FeSo4 and
safety of IHAT in this population.
Remove: Assessments are conducted at baseline, Day 15, and Day 85 of the supplementation period.
Secondary objectives are to assess the superiority of IHAT to ferrous sulphate and non-inferiority to
placebo in terms of side effects of diarrhoea.
 
Secondary endpoints could be referred to mechanistic endpoints. Further, mechanistic assessments, to
test whether IHAT reduces the burden of enteric pathogens, morbidity, and intestinal inflammation, and
that it does not cause detrimental changes to the gut microbiome, particularly in relation to 
,  and  .Lactobacillaceae Bifidobacteriaceae Enterobacteriaceae
 
Manuscript
Many readers will not know how iron is absorbed in the body so the authors are encouraged to simplify
and explain the basic physiology of iron absorption, the problem of oral iron compounds and therefore the
novel properties of IHAT.
 
Introduction
The authors provide an overview of ID and Anaemia. However, data on YLD and DALY are from adults
not specific to children. They then talk about data in children. Please add a sentence on how ID and
anaemia impact childhood development and illness to bring these two points closer together.
Also perhaps explain the difference between ID and Anaemia or simply refer to the problem as IDA
throughout
Before rationale and aims, introduce a further sub heading ‘the problem’ to highlight how normal iron
supplements do not work due to poor absorption and GI side effect. This is a key point to why IHAT is
needed and many readers simply will not know that of 200mg FeSo4 less that 5% is actually absorbed.
In rationale, please reduce the finer details of the compound and increase the background on earlier
preclinical studies. What have you shown so far?
Please list the aim (correct hb) and objectives (infection / side effects) as a separate subheading for clarity
(as above comments).
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(as above comments).
 
Protocol
Hypothesis is clear.
Remove comparator from this paragraph as that is a method.
Normally there is one primary endpoint then a series of secondary endpoints. It is confusing with 4
objectives. Please clarify through the manuscript the aim and objectives, primary and secondary
endpoints.
Remove details of any follow up study as not relevant to this protocol?
 
Study Design & Setting
Please use sub headings to the design and sponsorship etc. then Setting to highlight the population
(move details on transport of samples to methods not setting)
 
Criteria
Why exclude previous / current iron supplements – as if still have IDA then this is failure of therapy.
Is haemoglobinopathy excluded?
Childhood blood testing can be difficult – was this a criteria for inclusion i.e. a child must be well and able
to give a venous blood sample?
Intervention
Conducting, clinical trials in this setting is very difficult. There is clearly a labour intensive methodology.
Has this been validated (i.e. are these standardised methods in this setting) please provide a reference.
The trial preparations have been manufactured to enable concealment and therefor blinding of the
children. Are there blinded and unblinded assessors?
How is concealment bias ensured if there are weekly hb testing - are these results kept blinded also do all
children attend or only some – will there be reporting bias as only the sicker children return for repeat
testing?
Will children and healthcare workers be asked if they have an ideal of what intervention was given to
ensure lack of bias? It may be clear that a child’s health is improving and this may in turn lead to higher
compliance compared to a group where the intervention is causing side effects.
 
Outcomes
Resolving iron deficiency and anaemia correction are two separate endpoints. What is the definition of
resolving iron deficiency and also for correcting anaemia. A patient can have no anaemia but be iron
deficient and vice versa.
It seems the endpoint is Hb correction but hb rise > 1g/dl is not the same as an absolute correction of
anaemia. Should this endpoint be change in Hb?
Again, having 4 primary endpoints is unusual and difficult to comprehend in light of the aim and
objectives. Also the primary endpoint normally reflects the previous data, principle question and
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objectives. Also the primary endpoint normally reflects the previous data, principle question and
denominator of the power calculation. I suspect the funder/regulatory authority had input to this but I urge
a more simplified primary question.
If 705 to be consented and enrolled please use this number throughout for enrolment to the trial.
 
Discussion
As many of the patients have been enrolled, can the authors please highlight any interim analysis and
also (I assume) the DSMC have approved continuation.
 
Overall this is a superb study but I urge the authors to simplify to two questions – does IHAT work and is it
safe?
Is the rationale for, and objectives of, the study clearly described?
Partly
Is the study design appropriate for the research question?
Yes
Are sufficient details of the methods provided to allow replication by others?
No
Are the datasets clearly presented in a useable and accessible format?
Not applicable
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 06 Oct 2018
, University of Cambridge, UKDora Pereira
Many thanks for your valuable comments and for reviewing this protocol. We hope we have
address your reservations in the revised manuscript.
 
Here are some specific responses to some your comments.
 
The authors should not under estimate the novelty of the invention of a nano-iron and how
this works
 
We have tried to highlight better the novelty of IHAT and why it should work better than current oral
iron.  
 
 
The main issue is complexity of the primary endpoint. It is very unusual to have 4 primary
endpoints.
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In relation to the complexity of the primary endpoints, we do appreciate this point and assure the
reviewer that we thought very carefully about this and had several discussions with the several
independent review boards that have approved this protocol.  We felt that maintaining the
hypothesis-driven study design with the analysis of the 4 primary study endpoints is appropriate
taking into consideration the stage of development of IHAT and the fact that at the end of this trial 
 to move to the next stages of trials in resource-poorwe must be able to make a ‘go/no-go’ decision
settings. The ‘go’ decision to continue development of IHAT in these settings will only be justified if
we determine in this trial if IHAT can help correct iron deficiency anaemia   promotingwithout
diarrhoea, which is the largest limitation of  current supplements. This is why we maintained the
current 4 primary endpoints. 
-  Is this a Phase 2a? efficacy trial to test non-inferiority of IHAT to treat anaemia compared to
FeSo4 and safety of IHAT in this population.
 
This is a Phase II where we test both efficacy and safety as primary endpoint. We have added this
information to the abstract.
 
Secondary endpoints could be referred to mechanistic endpoints. Further, mechanistic
assessments, to test whether IHAT reduces the burden of enteric pathogens, morbidity, and
intestinal inflammation, and that it does not cause detrimental changes to the gut
microbiome, particularly in relation to  ,  and Lactobacillaceae Bifidobacteriaceae 
.Enterobacteriaceae
 
Thank you for this suggestion, we have included this.
- Many readers will not know how iron is absorbed in the body so the authors are encouraged to
simplify and explain the basic physiology of iron absorption, the problem of oral iron compounds
and therefore the novel properties of IHAT.
 
The protocol is already quite long and we don’t have much room to explain iron absorption and
metabolism. We do highlight better in the introduction what is unique about IHAT in relation to how
current oral iron is absorbed. So this should help the reader to understand the novelty.
-  Introduction
The authors provide an overview of ID and Anaemia. However, data on YLD and DALY are from
adults not specific to children. They then talk about data in children. Please add a sentence on how
ID and anaemia impact childhood development and illness to bring these two points closer
together.
Also perhaps explain the difference between ID and Anaemia or simply refer to the problem as IDA
throughout
Thank you, we have now done this in the revised version.
 
Adding more sub-headings for clarity.
 
This has been done, thank you.  
 
Protocol Remove comparator from this paragraph as that is a method.
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Protocol Remove comparator from this paragraph as that is a method.
 
We moved this paragraph to the design.
 
- Criteria
Why exclude previous / current iron supplements – as if still have IDA then this is failure of therapy.
They are excluded because treatment failure is a secondary outcome of the trial and we did not
want to have children currently taking iron supplements acting as confounders. But in practice, we
did not have to exclude any child due to them taking iron supplements currently since none of the ~
1500 children we screened had been screened for anaemia or was taking iron supplements in the
last year.
- Is haemoglobinopathy excluded?
Yes we had included these in the ‘chronic conditions’ criteria but now we have separated them.
 
Childhood blood testing can be difficult – was this a criteria for inclusion i.e. a child must be
well and able to give a venous blood sample?
 
Yes, these criteria are part of our inclusion (ability to follow the protocol which includes the blood
sampling). Our field nurses are very experienced and we have less than 5% of children where we
have been unable to collect venous blood in one of the study visits.
- Conducting, clinical trials in this setting is very difficult. There is clearly a labour intensive
methodology. Has this been validated (i.e. are these standardised methods in this setting) please
provide a reference.
Agreed! There were no existing validated procedures for our field procedures or for many of the
data and lab procedures. We spend the 1 year implementation period of the trial designing new
standardised protocols for all trial procedures (lab, field and data) and have currently 25
standardised study specific procedures that we are using in IHAT-GUT and that we can make
available to other researchers who would like to adapt them to their own studies. 
-  The trial preparations have been manufactured to enable concealment and therefore blinding of
the children. Are there blinded and unblinded assessors?
How is concealment bias ensured if there are weekly hb testing - are these results kept blinded
also do all children attend or only some – will there be reporting bias as only the sicker children
return for repeat testing?
The trial is double-blinded. All participants and field and lab staff are blinded. Each child has a
completely unique ‘drug’ code and therefore we don’t even know which children are in the same
treatment arm. Haemoglobin in 3 months does not change that much and the field staff who
measure Hb every week cannot determine which children will be on iron or placebo.
All children return to the clinics weekly unless they are travelling or mothers busy (~15% maximum
of missed visits) and this does not depend on their well status.
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of missed visits) and this does not depend on their well status.
Children do additional visits to the clinics if they have an adverse event.
- Will children and healthcare workers be asked if they have an idea of what intervention was given
to ensure lack of bias? It may be clear that a child’s health is improving and this may in turn lead to
higher compliance compared to a group where the intervention is causing side effects.
 
The health of every child in the study is improving simply due to all the extra care they receive
whilst taking part in the study, with daily visits by the field staff and weekly visits to a nurse. All
children that are sick with fever, diarrhoea etc are immediately treated. We must remember, this is
a setting where there is very limited health care and children hardly ever would see a nurse or
clinician unless they were severely sick. This is why it was so crucial in this study to have the
placebo arm to determine the true effects of giving iron above just providing standard health care
an no iron.
 
- Outcomes
Resolving iron deficiency and anaemia correction are two separate endpoints. What is the
definition of resolving iron deficiency and also for correcting anaemia. A patient can have no
anaemia but be iron deficient and vice versa.
The model we will use for iron deficiency in the presence of inflammation is referenced and we will
use the recommended method of the BRINDA group.
- It seems the endpoint is Hb correction but hb rise > 1g/dl is not the same as an absolute
correction of anaemia. Should this endpoint be change in Hb?
This is justified in the Discussion.
 
If 705 to be consented and enrolled please use this number throughout for enrolment to the
trial.
 
We have changed this.
- Discussion
As many of the patients have been enrolled, can the authors please highlight any interim analysis
and also (I assume) the DSMC have approved continuation.
 
Thanks, we have added a statement on this. 
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